Drug intelligence / Profile preview

ODS2005294

Development stage: Discontinued
Lead developer: Oncodesign
Modality: Small Molecules
Administration: Oral

Overview

**ODS2005294** is a potent and selective **LRRK2 kinase inhibitor** developed using Oncodesign's Nanocyclix® technology platform. It demonstrates strong inhibition of LRRK2 phosphorylation at S935, including ex vivo in peripheral blood mononuclear cells (PBMCs) from G2019S Parkinson's disease (PD) patients and asymptomatic relatives, good in vivo oral exposure, and high brain penetration, crossing the blood-brain barrier effectively. Jointly discovered with Ipsen, it was advanced as a potential therapeutic for PD targeting LRRK2 mutations but has since been discontinued.[1][2][3][7][9]

Targets

LRRK2 (Leucine-rich repeat serine/threonine-protein kinase 2)

Beyond the preview

Go deeper on ODS2005294.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ODS2005294.

Explore the full profile